Ainos (NASDAQ:AIMD) Stock Price Down 1.5% – Here’s What Happened

Ainos, Inc. (NASDAQ:AIMD) fell 1.5% during mid-day trading on Tuesday . The stock traded as low as $1.30 and last traded at $1.31. 17,485 shares traded hands during trading, a decline of 68% from the average daily volume of 55,193 shares. The stock had previously closed at $1.33.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Ainos Price Performance

The company has a quick ratio of 0.50, a current ratio of 0.55 and a debt-to-equity ratio of 1.58. The stock has a market cap of $11.59 million, a price-to-earnings ratio of -0.47 and a beta of 2.43. The company’s 50-day moving average is $1.89 and its 200-day moving average is $1.75.

Ainos (NASDAQ:AIMD) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter. Ainos had a negative return on equity of 160.55% and a negative net margin of 11,912.10%.

Insider Activity

In other news, Director Ting-Chuan Lee sold 109,988 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $1.90, for a total transaction of $208,977.20. Following the completion of the transaction, the director directly owned 807,417 shares in the company, valued at approximately $1,534,092.30. The trade was a 11.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $2.36, for a total transaction of $96,760.00. Following the completion of the sale, the insider directly owned 948,925 shares of the company’s stock, valued at $2,239,463. The trade was a 4.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have acquired 7,500 shares of company stock valued at $15,435 and have sold 179,788 shares valued at $359,247. Insiders own 9.79% of the company’s stock.

Hedge Funds Weigh In On Ainos

Institutional investors and hedge funds have recently made changes to their positions in the company. Mariner LLC bought a new stake in shares of Ainos in the 4th quarter valued at $37,000. Two Sigma Investments LP bought a new position in Ainos during the third quarter worth about $80,000. DRW Securities LLC lifted its holdings in Ainos by 272.6% during the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after acquiring an additional 48,439 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Ainos by 13.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after acquiring an additional 7,700 shares during the period.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.